https://www.selleckchem.com/pr....oducts/vls-1488-kif1
0 (mean, SD 21.6; N=491) versus oxaliplatin arm 63.2 (mean, SD 22; N=503); at 3 years 69.4 (SD 19.3; N=187) versus 65.4 (SD 22.2; N=202). After treatment and at 3 years, no significant differences (≥10 points) between groups were found in QoL subscales. Disease-free patients experiencing neurotoxic side-effects (grade 1-4) showed reduced GHS at 3 years versus patients without neurotoxicity (mean 59.2 versus 69.3; P0.001), while grade 3-4 rate was low. The addition of oxaliplatin was not associated with worse overall QoL
Mi piace
Commento
Condividi
